Stretched seven-day slide amid heightened volatility: Injective weekly outlook

Traders Union
All News
Crypto
Injective falls 8.73% this week

Highlights

Injective fell 8.73% on the week to $7.8, settling at the lower end of the recent price range.
Price sits near key support at $7.43, with resistance at $7.92, and volatility remains elevated.
Technical indicators show mixed momentum with strong buy signals from MACD and an oversold Stoch RSI, base case favors consolidation between $7.43 and $7.92 with an 80% probability of the price increasing toward $8.85.

Stablecoin partnership with BDACS shapes institutional flows amid regulatory push

Injective has entered into a memorandum of understanding with BDACS, a South Korean digital asset custodian, to integrate the KRW1 Korean won-backed stablecoin for settlement of tokenized real-world assets on its blockchain network, according to GlobeNewswire and TradingView. This partnership will allow institutions to settle transactions denominated in Korean won without relying on US dollar stablecoins, provided minting and redemption are limited to approved institutional partners and subject to regulatory approval. The collaboration aligns with South Korean authorities' ongoing efforts to define a regulatory framework for stablecoins, expected to see further developments through 2026.

Volatility spikes as MACD and Stoch RSI signal rebound risk after sell-off

The daily chart structure shows price settled at the very bottom of this week's range amid high volatility of 26.78%. Momentum character is defined by a sharp move lower without a sustained trend, and current momentum readings diverge: MACD signals a strong buy, while Stoch RSI is oversold at 19.3, suggesting potential for a rebound. Immediate support sits at $7.43, and resistance is marked by the Ichimoku Kijun at $7.92. These boundaries frame a market likely to remain reactive to shifts in sentiment.

Upside bias holds for next week as breakout hinges on resistance test

Over the coming week, the expected range is $6.74 to $8.85. There is a very high probability (more than 80%) of an increase, and a very low probability (less than 20%) of a decrease. The base case favors consolidation between $7.43 support and $7.92 resistance. A close above $7.92 could open the path toward the upper end of the expected range, while a break below $7.43 would expose $6.74.

Parshwa Turakhiya, analyst, sees regulatory momentum shaping sentiment around Injective this week as price hovers near $7.8 after a 9% decline. The memorandum of understanding with BDACS to integrate the KRW1 stablecoin stands out, potentially shifting settlement flows and institutional confidence as the market watches for clarity from South Korean authorities. Technically, daily volatility at 26.78% and a sharp drop leave Injective at the base of its range, while MACD and Stoch RSI suggest the stage is set for a possible rebound. The expected trading range is $6.74 to $8.85, bounded by support at $7.43 and resistance at $7.92. Base case is consolidation, with any move across these levels likely to trigger reactive sentiment. "New partnerships and regulatory steps will likely keep Injective traders on their toes — I’m watching for a rebound, but letting sentiment set the pace this week."

Earlier, analysts noted that Injective was exhibiting strong upside momentum supported by technical indicators, but cautioned that overbought conditions posed short-term pullback risks. With the current shift to a highly reactive trading environment and volatility on the rise, traders should closely monitor the $7.43 support and $7.92 resistance for potential breakout opportunities as regulatory news unfolds.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.